Synageva BioPharma gives update on sebelipase alfa

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Synageva BioPharma (GEVA) is out with an update on the development program for sebelipase alfa.

Enrollment is complete (and exceeded the target) in a Phase 3 trial in children and adults with LAL deficiency. Results expected in H2 2014.

Enrollment target met in Phase 2/3 trial in infants with LAL Deficiency. (PR)